318 related articles for article (PubMed ID: 31628926)
1. Inhibition of NAMPT markedly enhances plasma-activated medium-induced cell death in human breast cancer MDA-MB-231 cells.
Nagaya M; Hara H; Kamiya T; Adachi T
Arch Biochem Biophys; 2019 Nov; 676():108155. PubMed ID: 31628926
[TBL] [Abstract][Full Text] [Related]
2. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
3. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
[TBL] [Abstract][Full Text] [Related]
4. NAMPT inhibition sensitizes pancreatic adenocarcinoma cells to tumor-selective, PAR-independent metabolic catastrophe and cell death induced by β-lapachone.
Moore Z; Chakrabarti G; Luo X; Ali A; Hu Z; Fattah FJ; Vemireddy R; DeBerardinis RJ; Brekken RA; Boothman DA
Cell Death Dis; 2015 Jan; 6(1):e1599. PubMed ID: 25590809
[TBL] [Abstract][Full Text] [Related]
5. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
6. A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.
Song TY; Yeh SL; Hu ML; Chen MY; Yang NC
Biogerontology; 2015 Dec; 16(6):789-800. PubMed ID: 26330291
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress.
Xu R; Yuan Z; Yang L; Li L; Li D; Lv C
Oncol Rep; 2017 Sep; 38(3):1767-1773. PubMed ID: 28714034
[TBL] [Abstract][Full Text] [Related]
8. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
9. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
10. FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.
Hasmann M; Schemainda I
Cancer Res; 2003 Nov; 63(21):7436-42. PubMed ID: 14612543
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), an enzyme essential for NAD+ biosynthesis, in human cancer cells: metabolic basis and potential clinical implications.
Tan B; Young DA; Lu ZH; Wang T; Meier TI; Shepard RL; Roth K; Zhai Y; Huss K; Kuo MS; Gillig J; Parthasarathy S; Burkholder TP; Smith MC; Geeganage S; Zhao G
J Biol Chem; 2013 Feb; 288(5):3500-11. PubMed ID: 23239881
[TBL] [Abstract][Full Text] [Related]
12. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
13. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of glutamine metabolism increases sensitivity to plasma-activated medium-induced cytotoxicity.
Tanaka S; Hayashi S; Otsuka T; Kamiya T; Ishikawa K; Hara H
Free Radic Res; 2024 Mar; 58(3):170-179. PubMed ID: 38511644
[TBL] [Abstract][Full Text] [Related]
15. On-target effect of FK866, a nicotinamide phosphoribosyl transferase inhibitor, by apoptosis-mediated death in chronic lymphocytic leukemia cells.
Gehrke I; Bouchard ED; Beiggi S; Poeppl AG; Johnston JB; Gibson SB; Banerji V
Clin Cancer Res; 2014 Sep; 20(18):4861-72. PubMed ID: 25172933
[TBL] [Abstract][Full Text] [Related]
16. Oleate ameliorates palmitate-induced reduction of NAMPT activity and NAD levels in primary human hepatocytes and hepatocarcinoma cells.
Penke M; Schuster S; Gorski T; Gebhardt R; Kiess W; Garten A
Lipids Health Dis; 2017 Oct; 16(1):191. PubMed ID: 28974242
[TBL] [Abstract][Full Text] [Related]
17. Association of ABC Transporter With Resistance to FK866, a NAMPT Inhibitor, in Human Colorectal Cancer Cells.
Ogino Y; Sato A; Kawano Y; Aoyama T; Uchiumi F; Tanuma SI
Anticancer Res; 2019 Dec; 39(12):6457-6462. PubMed ID: 31810909
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
19. NAMPT suppresses glucose deprivation-induced oxidative stress by increasing NADPH levels in breast cancer.
Hong SM; Park CW; Kim SW; Nam YJ; Yu JH; Shin JH; Yun CH; Im SH; Kim KT; Sung YC; Choi KY
Oncogene; 2016 Jul; 35(27):3544-54. PubMed ID: 26568303
[TBL] [Abstract][Full Text] [Related]
20. NAD metabolism fuels human and mouse intestinal inflammation.
Gerner RR; Klepsch V; Macheiner S; Arnhard K; Adolph TE; Grander C; Wieser V; Pfister A; Moser P; Hermann-Kleiter N; Baier G; Oberacher H; Tilg H; Moschen AR
Gut; 2018 Oct; 67(10):1813-1823. PubMed ID: 28877980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
